SIGA (SIGA) 10-K 6 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information Document - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 28, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	SIGA TECHNOLOGIES INC
Entity Central Index Key	1,010,086
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	SIGA
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		79,039,000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 239,883,144

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 19,857,833	$ 28,701,824
Restricted cash, short-term	10,701,305	10,138,890
Accounts receivable	1,802,107	3,154,370
Inventory	2,983,249	26,209,964
Prepaid expenses and other current assets	2,019,999	954,426
Total current assets	37,364,493	69,159,474
Property, plant and equipment, net	138,640	299,477
Restricted cash, long-term	6,542,448	17,333,332
Deferred costs	96,592,334	72,649,277
Deferred tax asset, net	2,431,963	0
Goodwill	898,334	898,334
Other assets	702,167	642,083
Total assets	144,670,379	160,981,977
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
Accounts payable	1,328,867	2,517,072
Accrued expenses and other current liabilities	5,481,579	4,584,752
Total current liabilities	6,810,446	7,101,824
Deferred revenue	377,641,485	367,483,905
Warrant liability	11,466,162	6,727,409
Deferred income tax liability, net	0	286,066
Other liabilities	840,253	247,989
Long-term debt	71,050,324	66,553,053
Total liabilities	467,808,670	448,400,246
Stockholders’ deficiency
Common stock ($.0001 par value, 600,000,000 shares authorized, 79,039,000 and 78,692,612 issued and outstanding at December 31, 2017, and December 31, 2016, respectively)	7,904	7,869
Additional paid-in capital	214,229,581	213,714,154
Accumulated deficit	(537,375,776)	(501,140,292)
Total stockholders’ deficiency	(323,138,291)	(287,418,269)
Total liabilities and stockholders’ deficiency	$ 144,670,379	$ 160,981,977

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2015
Balance Sheet Parenthetical [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	79,039,000	79,039,000
Common stock, shares outstanding	78,692,912	78,692,912

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues
Research and development	$ 12,268,960	$ 14,987,628	$ 8,175,878
Operating expenses
Selling, general and administrative	12,303,050	13,713,635	10,582,068
Research and development	16,679,712	19,710,673	13,130,529
Patent expenses	909,946	909,376	1,009,053
Litigation expense	0	0	14,407,494
Lease termination	1,225,421	0	0
Interest on PharmAthene liability	0	11,668,900	0
Total operating expenses	31,118,129	46,002,584	39,129,144
Operating loss	(18,849,169)	(31,014,956)	(30,953,266)
Interest expense	14,758,140	2,395,517	266,726
Loss from increase in fair value of warrant liability	4,738,753	894,785	0
Backstop fee	0	(1,764,240)	0
Other income, net	16,788	102,324	42,202
Reorganization items, net	0	(3,716,902)	(7,811,551)
Loss before income taxes	(38,329,274)	(39,684,076)	(38,989,341)
Benefit/(Provision) for income taxes	2,093,790	(13,884)	(461,983)
Net and comprehensive loss	$ (36,235,484)	$ (39,697,960)	$ (39,451,324)
Earnings (loss) per share: basic and diluted (usd per share)	$ (0.46)	$ (0.69)	$ (0.73)
Weighted average shares outstanding: basic and diluted (in shares)	78,874,494	57,188,503	53,777,687

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Stock Options and Warrants	Stock Options and WarrantsCommon Stock	Stock Options and WarrantsAdditional Paid-in Capital	Restricted Stock Units (RSUs)	Restricted Stock Units (RSUs)Common Stock	Restricted Stock Units (RSUs)Additional Paid-in Capital	Stock Options	Stock OptionsCommon Stock	Stock OptionsAdditional Paid-in Capital	RSUs and Stock-Settled Appreciation RightsCommon Stock	RSUs and Stock-Settled Appreciation RightsAdditional Paid-in Capital
Total stockholders' equity (in shares) at Dec. 31, 2014		53,504,296
Total stockholders' equity at Dec. 31, 2014	$ (246,502,477)	$ 5,351	$ 175,483,180	$ (421,991,008)	$ 0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(39,451,324)			(39,451,324)
Issuance of common stock upon exercise of stock options and warrants (in shares)							610,000
Issuance of common stock upon exercise of stock options and warrants						$ 12,200	$ 60	$ 12,140
Stock-based compensation	1,528,582		1,528,582
Change in excess tax benefit stock-based compensation, value	(15,531)		(15,531)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ 0
Total stockholders' equity (in shares) at Dec. 31, 2015	78,692,912	54,114,296
Total stockholders' equity at Dec. 31, 2015	$ (284,428,550)	$ 5,411	177,008,371	(461,442,332)	0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(39,697,960)			(39,697,960)
Issuance of common stock upon exercise of stock options and warrants (in shares)										(483,335)
Issuance of common stock upon exercise of stock options and warrants									$ 0	$ 48	$ (48)
Stock-based compensation	775,541		775,541
Change in excess tax benefit stock-based compensation, value	0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)		(136,744)
Payment of common stock tendered for employee stock-based compensation tax obligations	(428,009)	$ (13)	(427,996)
Issuance of common stock associated with rights offering, shares		23,523,195
Issuance of common stock associated with rights offering, value	34,596,469	$ 2,352	34,594,117
Issuance of common stock associated with backstop agreement, shares		708,530
Issuance of common stock associated with backstop agreement, value	1,764,240	$ 71	1,764,169
Total stockholders' equity (in shares) at Dec. 31, 2016		78,692,612
Total stockholders' equity at Dec. 31, 2016	(287,418,269)	$ 7,869	213,714,154	(501,140,292)	0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(36,235,484)			(36,235,484)
Issuance of common stock upon exercise of stock options and warrants (in shares)													(33,870)		466,328
Issuance of common stock upon exercise of stock options and warrants												$ 89,498	$ 3	$ 89,495	$ 47	$ (47)
Stock-based compensation	1,101,031		1,101,031
Change in excess tax benefit stock-based compensation, value	0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)		(153,810)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ (591,067)	$ (15)	(591,052)
Buy-back of stock options			(84,000)
Total stockholders' equity (in shares) at Dec. 31, 2017	78,692,912	79,039,000
Total stockholders' equity at Dec. 31, 2017	$ (323,138,291)	$ 7,904	$ 214,229,581	$ (537,375,776)	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (36,235,484)	$ (39,697,960)	$ (39,451,324)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and other amortization	132,189	174,275	247,357
Loss on change in fair value of warrant liability	4,738,753	894,785	0
Lease termination	1,225,421	0	0
Stock-based compensation	1,101,031	775,541	1,574,038
Deferred income taxes (benefit)/provision	(2,718,029)	20,423	21,103
Write down of inventory, net	536,000	0	0
Non-cash backstop fee	0	(1,764,240)	0
Loss on disposal of assets	0	0	243,707
Non-cash interest expense	4,497,271	566,779	10,052
Interest expense on term loan-paid with restricted cash	10,228,469	1,222,222	0
Changes in assets and liabilities:
Accounts receivable	1,352,263	522,360	(3,185,098)
Inventory	22,690,715	(13,762,876)	6,597,389
Deferred costs	(23,943,057)	(19,712,849)	(20,075,554)
Prepaid expenses and other current assets	(1,065,573)	(330,443)	229,266
Other assets	(60,084)	80,928	0
Accounts payable, accrued expenses and other current liabilities	(1,847,427)	(177,342)	1,862,779
Liabilities subject to compromise	0	(160,072,170)	(192,067,797)
Deferred revenue	11,412,898	112,225,534	255,176,572
Other liabilities	(203,654)	(84,228)	(73,107)
Net cash (used in) provided by operating activities	(8,158,298)	(115,590,781)	11,109,383
Cash flows from investing activities:
Capital expenditures	(100,124)	(23,927)	(108,953)
Return of collateral for surety bond	0	1,212,591	0
Restricted cash	0	0	4,000,000
Net cash (used in) provided by investing activities	(100,124)	1,188,664	3,891,047
Cash flows from financing activities:
Issuance of common stock upon exercise of stock options and warrants	89,498	0	12,200
Net proceeds from equity rights offering-net of offering costs	0	34,596,468	0
Payments for Repurchase of Common Stock	(84,000)	0	0
Payment of employee tax obligations for common stock tendered	(591,067)	(428,009)	0
Debt issuance costs	0	(3,775,546)	0
Repayment of long-term debt	0	0	(2,000,000)
Excess tax benefit from stock-based compensation	0	0	(15,531)
Net cash (used in) provided by financing activities	(585,569)	30,392,913	(2,003,331)
Net decrease/increase in cash and cash equivalents	(8,843,991)	(84,009,204)	12,997,099
Cash and cash equivalents at beginning of period	28,701,824	112,711,028	99,713,929
Cash and cash equivalents at end of period	19,857,833	28,701,824	112,711,028
Supplemental disclosure of cash flows information:
Portion of Term Loan paid directly to PharmAthene by the Lender in satisfaction of the PharmAthene claim; such liability is part of the Liabilities Subject to Compromise line item	0	46,900,000,000,000	0
Cash interest paid on PharmAthene liability	0	11,668,900,000,000	0
Cash interest paid on Term Loan from restricted cash	10,288,469,000,000	1,222,222,000,000	0
Cash income taxes paid (refund)	325,000,000,000	500,975,000,000	(420,029,000,000)
Fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability	$ 0	$ 5,832,624,000,000	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	Organization and Basis of Presentation Description of Business SIGA Technologies, Inc. (“SIGA” or the “Company”) is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. In December of 2017, the Company submitted a New Drug Application (“NDA”) to the U.S Food and Drug Administration ( “ FDA ” ) for TPOXX ® . In February 2018, the Company received notice that the FDA granted priority review of the NDA and that the FDA's target final action date is August 8, 2018. Liquidity The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is not entitled to receive additional procurement-related payments under the current BARDA Contract ( Note 3 ) if and until FDA approval of TPOXX® has been achieved, and there is no difference between the approved product and courses of TPOXX® that have been delivered to the U.S. Strategic National Stockpile ( “ Strategic Stockpile ” ). Upon meeting the aforementioned requirements, a determination of which is currently expected in the third quarter of 2018, the Company will be entitled to a $41 million hold back payment under the BARDA Contract. In the event that the Company does not receive a substantial portion of the hold back payment, or other substantial cash inflows, by October of 2018, then, based on currently forecasted operating costs, the Company will require additional sources of funding to continue operations and prevent an event of default under the term loan ( Note 7 ). In this case, the Company would seek to increase cash liquidity by: raising proceeds through a financing, entering into a new contract for TPOXX® or any other product, a sale of assets, or the modification of the existing BARDA Contract; significantly reducing its operating expenses; or modifying the terms of the Term Loan Agreement. There can be no assurance that TPOXX® will receive FDA approval on a timely basis, if at all, or that there will be no difference between the approved product and courses of TPOXX® that have been delivered to the Strategic Stockpile. Furthermore, there can be no assurance that the Company would be able to increase cash liquidity, if needed, through a financing, a new contract for TPOXX® or any other product, a sale of assets, the modification of the existing BARDA Contract, or a significant reduction of its operating expenses or operations, or that the lenders would agree to modify the Term Loan Agreement, if needed. Because of these conditions, substantial doubt exists about the Company's ability to continue as a going concern for one year from the financial statement issuance date. Closing of Chapter 11 On April 12, 2016, the Company emerged from chapter 11 of the Bankruptcy Code when the Company's plan of reorganization (the “Plan”) became effective, and on December 22, 2016 the Company's chapter 11 case was closed by the Bankruptcy Court. Under the Plan, the Company fully paid all of its claims. The Company did not apply the provisions of fresh start accounting as ownership of existing shares of the Company's common stock remained unaltered by the Plan. Prior to April, 12 2016, the effective date of the Plan, the Company was operating its business as a “debtor-in-possession.” The Company had filed on September 16, 2014, a voluntary petition for relief under chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) chapter 11 Case Number 14-12623 (SHL). The chapter 11 case preserved the Company's ability to satisfy its commitments under the BARDA Contract (as defined in Note 3 ) and preserved its operations, which likely would have been jeopardized by the enforcement of a judgment stemming from the Company's litigation with PharmAthene, Inc. (“PharmAthene”) (see “PharmAthene Litigation” below). While operating as a debtor-in-possession under chapter 11, the Company pursued an appeal of the Delaware Court of Chancery Final Order and Judgment, without having to post a bond. PharmAthene Litigation On November 16, 2016, the Company satisfied the Judgment (as defined in Note 12 ) owed to PharmAthene in connection with the Company's litigation with PharmAthene. In total, PharmAthene was paid $217.0 million in connection with the Judgment. See Note 12 for additional details related to this litigation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The consolidated financial statements and related disclosures are prepared in conformity with accounting principles generally accepted in the United States of America. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the periods reported. The most significant estimates include the variables used in the calculation of fair value of stock-based awards and warrants granted or issued by the Company; reported amounts of revenue; and the realization of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates. Basis of Presentation The consolidated financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented. Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Restricted Cash and Cash Equivalents A portion of the Company’s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for $5 million , cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned $5 million in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. As of December 31, 2017, the restricted cash balance was $17.2 million of which $10.7 million is designated as a current asset and the remainder is designated as non-current. See Note 7 for additional information. Concentration of Credit Risk The Company has cash in bank accounts that exceed the Federal Deposit Insurance Corporation insured limits. The Company has not experienced any losses on its cash accounts and no allowance has been provided for potential credit losses because management believes that any such losses would be minimal, if any. Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2017 and 2016 , 100% of accounts receivables represented receivables from Biomedical Advanced Research and Development Authority (“BARDA”) and National Institutes of Health (“NIH”). An allowance for doubtful accounts is based on specific analysis of the receivables. At December 31, 2017 and 2016 , the Company had no allowance for doubtful accounts. Inventory Inventory is stated at the lower of cost or net realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may expire prior to expected sale or has a cost basis in excess of its net realizable value. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such unmarketable inventory to its net realizable value. As of December 31, 2017, inventory is expected to have a shelf life in excess of five years and is expected to be available for delivery under any new procurement contracts. Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five years for laboratory equipment; three years for computer equipment; and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance, repairs and minor replacements are charged to expense as incurred. Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, collectability is reasonably assured, title and risk of loss have been transferred to the customer and there are no further contractual obligations. Certain arrangements may provide for multiple deliverables, in which there may be a combination of: up-front licenses; research, development, regulatory or other services; and delivery of product. Multiple deliverable arrangements can be divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (i) the delivered item(s) have value to the customer on a standalone basis and (ii) in circumstances in which an arrangement includes a general right of return with respect to delivered items, then performance of the remaining deliverables must be considered probable and substantially in control of the Company. If multiple deliverables cannot be divided into separate units of accounting then the deliverables must be combined into a single unit of accounting. Total consideration in a multiple deliverable arrangement is allocated to units of accounting on a relative fair value of selling price basis. Consideration allocated to a delivered item or unit of accounting is limited to the amount that is not contingent upon delivery of additional items. Direct costs incurred by the Company and associated with the deferral of revenue for a unit of accounting are also deferred and are recognized as expenses in the same period that the related deferred revenue is recognized as revenue. Subject to the above, payments for development activities are recognized as revenue when earned, over the period of effort. Funding for the acquisition of capital assets under cost-plus-fee contracts or grants is evaluated for appropriate recognition as a reduction to the cost of the asset, a financing arrangement, or revenue based on the specific terms of the related grant or contract. For the years ended December 31, 2017 , 2016 , and 2015 , revenues from BARDA and NIH were 100% of total revenues recognized by the Company. Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to the BARDA Contract, including employee related costs, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no alternative future uses, are expensed as incurred. Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value. Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value was estimated using the Black-Scholes model and for stock-settled stock appreciation rights (“SSARs”), fair value was estimated using the Monte Carlo method. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods in the Company’s consolidated statement of operations. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not that some or the entire deferred tax asset will not be realized. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain. Net Loss per Share The objective of basic earnings per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The Company incurred losses for the years ended December 31, 2017 , 2016 and 2015 . For all periods presented, all equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of: Year Ended December 31, 2017 2016 2015 Stock Options 1,386,176 1,789,751 2,047,083 Stock-Settled Stock Appreciation Rights (“SSAR”) 333,252 360,031 368,331 Restricted Stock Units 1,396,730 705,850 700,265 Warrants 2,690,950 877,303 82,192 As discussed in Note 10 , the appreciation of each SSAR was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued. Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 – Quoted prices for identical instruments in active markets. • Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. • Level 3 – Instruments where significant value drivers are unobservable to third parties. The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of common stock warrants on a recurring basis and classify such liability-classified warrants in Level 3. As described in Note 8 , the fair value of the liability-classified warrant was $11.5 million at December 31, 2017 . At December 31, 2017 , the fair value of the debt was $74.1 million and the carrying value of the debt was $71.0 million . The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement. The fair value of the loan was measured using Level 3 inputs. The discount rate was determined using market participant assumptions. There were no transfers between levels of the fair value hierarchy during 2017. In addition, there were no Level 1 or Level 2 financial instruments as of December 31, 2017 and 2016. The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs: Fair Value Measurements of Level 3 liability classified warrant Warrant liability at December 31, 2016 $ 6,727,409 Increase in fair value of warrant liability 4,738,753 Warrant liability at December 31, 2017 $ 11,466,162 Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. We record anticipated recoveries under existing insurance contracts when recovery is assured. Segment Information The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer, who is the Chief Operating Decision Maker. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and has only one reportable segment. Revision In connection with the preparation of the consolidated financial statements for the year ended December 31, 2017, the Company identified that its warrant liability was incorrectly classified as a current liability on the December 31, 2016 balance sheet. The 2016 balance sheet has been revised to properly classify the warrant liability as a long-term liability. This revision does not impact the consolidated statement of operations and comprehensive loss, the consolidated statement of cash flows or the consolidated statement of changes in stockholders’ deficiency for the year ended December 31, 2016 and is not considered material to the previously issued consolidated financial statements or the current consolidated financial statements for the year ended December 31, 2017 as a whole. Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) . The amendments in Part I of this ASU change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of this ASU recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company has elected to early adopt ASU No. 2017-11. which retained the liability classification of the Company's warrant and had no impact on the Company's consolidated financial statements. On May 10, 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718)-Scope of Modification Accounting . The guidance clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for financial statements issued for fiscal years beginning after December 13, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company believes the adoption of ASU No. 2017-09 will not have a significant impact on its consolidated financial statements. On January 26, 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. The same one-step impairment test will be applied to goodwill at all reporting units, even those with zero or negative carrying amounts. The revised guidance will be applied prospectively, and is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company believes the adoption of ASU No. 2017-04 will not have a significant impact on its consolidated financial statements. On November 17, 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force . The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The guidance requires application using a retrospective transition method. The Company believes the adoption of ASU No. 2016-18 will have a significant impact due to the fact the Company will reflect sources and uses of restricted cash in the consolidated statement of cash flows and provide a reconciliation of restricted cash balances. On August 26, 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), a consensus of the FASB’s Emerging Issues Task Force . The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company believes the adoption of ASU No. 2016-15 will not have a significant impact on its consolidated financial statements. In March 2016, the FASB amended the existing accounting standards for stock-based compensation, ASU No. 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments impact several aspects of accounting for share-based payment transactions, including the income tax consequences, expected forfeitures, classification of awards as either equity or liabilities, and classification in the statement of cash flows. The Company adopted the amendments in the first quarter of 2017. Prior to adoption of ASU No. 2016-09, tax attributes related to stock option windfall deductions were not recorded until they resulted in a reduction of cash tax payable. As of December 31, 2016, the excluded windfall deductions for federal and state purposes were $1.6 million . Upon adoption of ASU No. 2016-09, the Company recognized the excluded windfall deductions as a deferred tax asset with a corresponding offset to the valuation allowance. With regard to the forfeiture policy election, we will continue to estimate the number of awards expected to be forfeited. On February 25, 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842) , which relates to the accounting for leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-02 will have on its consolidated financial statements. The Company expects its real estate leases to be capitalized on its balance sheet. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition-Construction-Type and Production-Type Contracts. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim periods beginning after December 15, 2016. The Company will adopt this standard in the first quarter of 2018 using the modified retrospective method, which will not change any of the historical financial results previously reported by the Company. Any adjustment upon adoption will be recorded as an accumulated adjustment due to a change in accounting in the stockholders' deficiency section of the Company's consolidated balance sheet. The Company has determined that revenue connected with courses of TPOXX ® delivered to BARDA and related services, milestones and advance payments (activities in combination that constitute one performance obligation) will be recognized at a point in time when the constraint on revenue (quantification, and specification, of any possible replacement obligation) has been resolved. Currently, the revenue constraint is not expected to be resolved prior to adoption of this standard. As such, the Company does not expect adoption of this standard to have an impact on the timing of revenue recognition for the above-mentioned activities. Separately, the Company has determined that revenue for performance obligations associated with R&D activities will be recognized over time similar in manner to the Company’s historical approach. As a result, the Company believes the adoption of ASU No.2014-09 will not have a significant impact on its consolidated financial statements.

Procurement Contract and Resear

Procurement Contract and Research Agreements	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Procurement Contract and Research Agreements	Procurement Contract and Research Agreements Procurement Contract On May 13, 2011, the Company signed a contract with the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) pursuant to which SIGA agreed to deliver two million courses of TPOXX® to the Strategic Stockpile. The contract with BARDA (as amended, modified, or supplemented from time to time, the “BARDA Contract”) includes a base contract (“Base Contract”) as well as options (described below). The Base Contract contemplates approximately $472.3 million of payments, of which $409.8 million is consideration for the manufacture and delivery of 1.7 million courses of TPOXX® and $62.5 million is available for certain development and supportive activities. Under the Base Contract, BARDA has agreed to buy from the Company 1.7 million courses of TPOXX®. Additionally, the Company has agreed to contribute to BARDA 300,000 courses at no additional cost to BARDA. A total of 2.0 million courses of TPOXX® is required to be delivered to the Strategic Stockpile in order for the Company to be eligible to receive a $40.9 million hold back payment (see description of hold back payment below). For courses of TPOXX® that are physically delivered to the Strategic Stockpile, the Company has replacement obligations, at no cost to BARDA, in the event that the final version of TPOXX® approved by the FDA is different from any courses of TPOXX® that have been delivered to the Strategic Stockpile or if TPOXX® does not meet any specified label claims, fails release testing or does not meet the 38-month expiry period (from time of delivery to the Strategic Stockpile), or if TPOXX® is recalled or deemed to be recalled for any reason. As of December 31, 2017 , the Company has received $368.9 million under the Base Contract related to the manufacture and physical delivery of courses of TPOXX®. Included in this amount are a $41.0 million advance payment in 2011 for the completion of certain planning and preparatory activities related to the Base Contract, a $12.3 million milestone payment in 2012 for the completion of the product labeling strategy for TPOXX®, an $8.2 million milestone payment in 2013 for the completion of the commercial validation campaign for TPOXX®, a $20.5 million milestone payment in 2016 for submission of documentation to BARDA indicating that data covering the first 100 subjects enrolled in the phase III pivotal safety study had been submitted to and reviewed by a Data Safety and Monitoring Board (“DSMB”) and that such DSMB had recommended continuation of the safety study, as well as submission of the final pivotal rabbit efficacy study report to the FDA, and $286.9 million of payments for physical deliveries of TPOXX® to the Strategic Stockpile beginning in 2013. As of December 31, 2017 , the Company has cumulatively delivered 2.0 million courses of TPOXX® to the Strategic Stockpile. The dosage of courses delivered is 600 mg administered twice per day (1,200 mg per day). In February 2016, the FDA confirmed (through dose concurrence) its earlier dosage guidance of 600 mg administered twice per day (1,200 mg per day). Courses delivered to the Strategic Stockpile are currently subject to a product replacement obligation (as discussed above). As of December 31, 2017 , the Company is eligible under the Base Contract to receive a $40.9 million hold back payment, which represents an approximate 10% hold back on the $409.8 million of total payments related to the manufacture and delivery of 1.7 million courses of TPOXX® under the Base Contract. The $40.9 million hold back payment would be triggered by FDA approval of TPOXX®, as long as the Company does not have a continuing product replacement obligation to BARDA. In addition to the Base Contract, the BARDA Contract also includes remaining options that, if all were exercised by BARDA, would result in aggregate payments to the Company of $122.7 million , including: a $50.0 million payment to the Company in the event of FDA approval for extension to 84-month expiry for TPOXX® (from 38-month expiry as required in the Base Contract); up to $58.3 million of funding for development and supportive activities such as work on a smallpox prophylaxis indication for TPOXX®; and/or $14.4 million of funding for production-related activities related to warm-base manufacturing. In 2015, BARDA exercised two options related to extending the indication of the drug to the geriatric and pediatric populations. The stated value of these exercises was minimal. BARDA, in its sole discretion, may choose not to exercise unexercised options. However, BARDA has indicated that it will evaluate, after the FDA’s review and evaluation of stability data, the Company's request that BARDA exercise the option for the $50.0 million payment to the Company in the event of FDA approval of 84-month expiry for TPOXX®. The BARDA Contract expires in September 2020. The BARDA Contract is a multiple deliverable arrangement comprising delivery of courses and covered research and development activities. The BARDA Contract provides certain product replacement rights with respect to delivered courses. For this reason, recognition of revenue that might otherwise occur upon delivery of courses is expected to be deferred until the Company’s obligations related to potential replacement of delivered courses are satisfied. The Company assessed the selling price for each of the aforementioned deliverables-research and development activities and drug product. The selling price of certain reimbursed research and development services was determined by reference to existing and past research and development grants and contracts between the Company and various government agencies. The selling price of drug product was determined by reference to other companies’ sales of drug products such as antiviral therapeutics, orphan drugs and drugs with potential life-saving impact similar to TPOXX®, including products delivered to the Strategic Stockpile. The Company has recognized revenue for reimbursement of certain BARDA Contract research and development services. Cash inflows related to delivery of courses are recorded as deferred revenue. In addition, direct costs incurred by the Company to fulfill the delivery of courses including the supplementing of courses previously delivered under the BARDA Contract are being deferred and will be recognized as expenses in the same period that the related deferred revenue is recognized as revenue. As of December 31, 2017 and December 31, 2016, deferred direct costs under the BARDA Contract of approximately $96.5 million and $72.2 million , respectively, are included in deferred costs on the consolidated balance sheets. As of December 31, 2017, the Company recorded $377.6 million of deferred revenue in connection with the BARDA contract. This amount has been recorded for the delivery of courses of TPOXX® to the Strategic Stockpile and certain supportive services provided as part of the BARDA Contract. For the year ended December 31, 2017 revenue from reimbursed research and development was $9.0 million . Research Agreements and Grants The Company has an R&D program for the intravenous (IV) formulation of TPOXX®. This program is funded by a development contract with BARDA. The development contract has a period of performance that terminates on December 30, 2020. As of December 31, 2017, the development contract provides for future aggregate research and development funding of approximately $12.9 million . Contracts and grants include, among other things, options that may or may not be exercised at the U.S. Government’s discretion. Moreover, contracts and grants contain customary terms and conditions including the U.S. Government’s right to terminate or restructure a contract or grant for convenience at any time. As such, we may not be able to utilize all available funds.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	Inventory Due to the deferral of revenue under the BARDA Contract (see Note 3 for additional information), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs on the consolidated balance sheets. The value of inventory represents the costs incurred to manufacture TPOXX®. Inventory consisted of the following: As of December 31, 2017 December 31, 2016 Work in-process $ 2,025,445 $ 18,916,084 Finished goods 957,804 7,293,880 Inventory $ 2,983,249 $ 26,209,964 For the years ended December 31, 2017 and 2016, research and development expenses include net inventory-related losses of approximately $536,000 and $0 , respectively. The $536,000 loss for the year ended December 31, 2017 relates to a $686,000 inventory write-down, partially offset by credits received from contract manufacturing organizations (“CMO”) in connection with the inventory write-down.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consisted of the following: As of December 31, 2017 December 31, 2016 Leasehold improvements $ 2,420,028 $ 2,542,044 Computer equipment 701,762 770,479 Furniture and fixtures 363,588 455,220 3,485,378 3,767,743 Less-accumulated depreciation (3,346,738 ) (3,468,266 ) Property, plant and equipment, net $ 138,640 $ 299,477 Depreciation and amortization expense on property, plant, and equipment was $132,189 , $174,275 , and $247,357 for the years ended December 31, 2017 , 2016 , and 2015 , respectively. In connection with the lease termination discussed in Note 13 , the Company wrote off $129,000 of leasehold improvements and furniture and fixtures during the year ended December 31, 2017.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses and other current liabilities consisted of the following: As of December 31, 2017 December 31, 2016 Bonus $ 2,538,340 $ 2,357,194 Deferred revenue-R&D for TPOXX ® intravenous formulation 1,255,318 — Professional fees 381,980 481,641 Vacation 328,588 262,664 Other 977,353 1,483,253 Accrued expenses and other current liabilities $ 5,481,579 $ 4,584,752

Debt

Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt	Debt On September 2, 2016, the Company entered into a loan and security agreement (as amended from time to time, the “Loan Agreement”) with OCM Strategic Credit SIGTEC Holdings, LLC (“Lender”), pursuant to which the Company received $80.0 million (less fees and other items) on November 16, 2016 having satisfied certain pre-conditions. Such $80.0 million had been placed in an escrow account on September 30, 2016 (the “Escrow Funding Date”). Prior to the Escrow Release Date (November 16, 2016), the Company did not have access to, or any ownership interest in, the escrow account. Until the Escrow Release Date occurred, the Company did not have an obligation to make any payments under the Loan Agreement, no security was granted under the Loan Agreement and no affirmative or negative covenants or events of default were effective under the Loan Agreement. Amounts were held in the escrow account until the satisfaction of certain conditions including the closing of the Rights Offering (see Note 9 ) on November 16, 2016. As part of the satisfaction of the PharmAthene claim, funds were released from the escrow account (the date on which such transfer occurred, the (“Escrow Release Date”). The Loan Agreement provides for a first-priority senior secured term loan facility in the aggregate principal amount of $80.0 million (the “Term Loan”), of which (i) $25.0 million was placed in a reserve account (the “Reserve Account”) only to be utilized to pay interest on the Term Loan as it becomes due; (ii) an additional $5.0 million was also placed in the Reserve Account and up to the full amount of such $5.0 million may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions, provided that any of such amount is required to fund any interest to the extent any interest in excess of the aforementioned $25.0 million is due and owing and any of such $5.0 million remains in the Reserve Account; and (iii) $50.0 million (net of fees and expenses then due and owing to the Lender) was paid to PharmAthene as part of the final payment to satisfy the PharmAthene claim. Interest on the Term Loan is at a per annum rate equal to the Adjusted LIBOR rate plus 11.5% , subject to adjustments as set forth in the Loan Agreement. At December 31, 2017, the effective interest rate on the Term Loan, which includes interest payments and accretion of unamortized costs and fees, was 18.8% . The Company incurred approximately $14.8 million of interest expense during the year-ended December 31, 2017, of which $10.3 million was paid from restricted cash and the remaining $4.5 million accreted to the Term Loan balance. The Term Loan shall mature on the earliest to occur of (i) the four-year anniversary of the Escrow Release Date, and (ii) the acceleration of certain obligations pursuant to the Loan Agreement. At maturity, $80.0 million of principal will be repaid, and an additional $4.0 million will be paid (see below). Prior to maturity, there are no scheduled principal payments. Through the three and one-half year anniversary of the Escrow Release Date, any prepayment of the Term Loan is subject to a make-whole provision in which interest payments related to the prepaid amount are due (subject to a discount of treasury rate plus 0.50% ). In connection with the Term Loan, the Company has granted the Lender a lien on and security interest in all of the Company’s right, title and interest in substantially all of the Company’s tangible and intangible assets, including all intellectual property. The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants. These covenants, among other things, require a minimum cash balance throughout the term of the Term Loan and the achievement of regulatory milestones by certain dates, and contain certain limitations on the ability of the Company to incur unreimbursed research and development expenditures over a certain threshold, make capital expenditures over a certain threshold, incur indebtedness, dispose of assets outside of the ordinary course of business and enter into certain merger or consolidation transactions. The aforementioned minimum cash requirement was $10.0 million and reduces to $5.0 million for 2018 until the earlier of (i) December 31, 2018 and (ii) 45 days after FDA approval of TPOXX®; thereafter, the minimum cash requirement will be $20.0 million . The Loan Agreement includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) the material inaccuracy of representations or warranties made thereunder, (iii) non-compliance with covenants thereunder, (iv) non-payment of amounts due under, or the acceleration of, other material indebtedness of the Company and (v) bankruptcy or insolvency events. Upon the occurrence and during the continuance of an event of default under the Loan Agreement, the interest rate may increase by 2.00% per annum above the rate of interest otherwise in effect, and the Lender would be entitled to accelerate the maturity of the Company’s outstanding obligations thereunder. As of December 31, 2017, the Company is in compliance with the Loan Agreement covenants. In connection with the Loan Agreement, the Company incurred $8.2 million of costs (including interest on amounts held in the escrow account between September 30, 2016 and November 15, 2016). Furthermore, an additional $4.0 million will become payable when principal of the Term Loan is repaid. As part of the Company's entry into the Loan Agreement, the Company issued the Warrant (see Note 8 ) with a fair market value of $5.8 million . The fair value of the Warrant, as well as costs related to the Term Loan issuance, were recorded as deductions to the Term Loan balance on the Balance Sheet. These amounts are being amortized using the effective interest method over the life of the related Term Loan. The $4.0 million that will be paid when principal is repaid is being accreted to the Term Loan balance each quarter on a per diem basis. As of December 31, 2017 the Term Loan balance is $71.1 million .

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Financial Instruments	Financial Instruments 2016 Warrant On September 2, 2016, in connection with the entry into the Loan Agreement (see Note 7 for additional information), the Company issued a warrant (the “ Warrant ” ) to the Lender to purchase a number of shares of the Company’s common stock equal to $4.0 million divided by the lower of (i) $2.29 per share and (ii) the subscription price paid in connection with the Rights Offering. The subscription price paid was $1.50 in connection with the Rights Offering; accordingly, the exercise price of the Warrant has been set at $1.50 per share, and there are 2.7 million shares underlying the Warrant. The Warrant provides for weighted average anti-dilution protection and is exercisable in whole or in part for ten ( 10 ) years from the date of issuance. The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reports its change in fair value in the consolidated statement of operations. On September 2, 2016, the issuance date of the Warrant, the fair value of the liability-classified Warrant was $5.8 million . The Company applied a Monte Carlo Simulation-model to calculate the fair value of the Warrant using the following assumptions: risk free interest rate of 1.60% ; no dividend yield; an expected life of 10 years; and a volatility factor of 80% . The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation. These models generated substantially equivalent fair values for the Warrant. As such, the Company utilized a Black-Scholes model for December 31, 2017 to determine the fair value of the Warrant. As of December 31, 2017 , the fair value of the Warrant was $11.5 million . A Black Scholes model was applied to calculate the fair value of the Warrant using the following assumptions: risk free interest rate of 2.38% ; no dividend yield; an expected life of 8.67 years; and a volatility factor of 75% . For the years ended December 31, 2017 and 2016, the Company recorded a loss of $4.7 million and $0.9 million , respectively as a result of increases in fair value of the liability-classified Warrant. At December 31, 2016, pursuant to the Warrant agreement, there were no conditions under which current assets would have been required to satisfy the Warrant obligation. As such, the December 31, 2016 consolidated balance sheet has been revised to reflect the Warrant as a long-term liability.

Stockholders' Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Deficiency	Stockholders’ Deficiency On December 31, 2017 , the Company’s authorized share capital consisted of 620,000,000 shares, of which 600,000,000 are designated common shares and 20,000,000 are designated preferred shares. The Company’s Board of Directors is authorized to issue preferred shares in series with rights, privileges and qualifications of each series determined by the Board. As of December 31, 2017 and 2016 , no preferred shares were outstanding or issued. Rights Offering On November 16, 2016, the Company completed a rights offering (the “Rights Offering”), pursuant to which it raised approximately $35.3 million in gross proceeds through the sale of 23,523,195 shares of its common stock. The Rights Offering was made pursuant to a registration statement on Form S-1 and declared effective by the SEC on October 21, 2016. As part of the Rights Offering, each stockholder of the Company received a subscription right for each share of common stock owned as of the record date of October 12, 2016. Each subscription right entitled its holder to invest $0.65 towards the purchase of shares of the Company's common stock at a subscription price equal to the lower of $1.50 or 85% of the volume weighted average price of Company shares during market hours on the expiration date of the Rights Offering. The Rights Offering expired on November 8, 2016. Through basic subscriptions and oversubscriptions, the Rights Offering was fully subscribed. The subscription price was set at $1.50 . The Company used the net proceeds of the Rights Offering, together with proceeds from the Term Loan and cash on hand, to fully satisfy PharmAthene's claim under the Plan. Rights Offering-Backstop Agreement On October 13, 2016, in connection with the Rights Offering as discussed above, the Company entered into an investment agreement or “backstop agreement”, with an affiliate of MacAndrews & Forbes Incorporated (“M&F”) (see Note 13 ), and certain other backstop parties (the “Backstop Parties”). Under the terms of the backstop agreement, the Backstop Parties agreed to purchase, pursuant to a separate private placement, a number of shares of common stock equal to the numbers of shares that were not subscribed for in the Rights Offering. Because the Rights Offering was fully subscribed, the Backstop Parties were not required to draw on such commitment. The Company issued 708,530 shares to Backstop Parties, of which approximately 565,000 shares were received by M&F, in payment of the five percent backstop fee ( $1,764,240 ) payable to the Backstop Parties in connection with the backstop agreement. The fair value of the shares issued in satisfaction of the backstop fee was expensed in the income statement in the fourth quarter of 2016. There are no remaining payment obligations to the Backstop Parties under the backstop agreement.

Stock Compensation Plans

Stock Compensation Plans	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Compensation Plans	Stock Compensation Plans The Company’s 2010 Stock Incentive Plan (the “2010 Plan”) was initially adopted in May 2010. The 2010 Plan provided for the issuance of stock options, restricted stock and unrestricted stock with respect to an aggregate of 2,000,000 shares of the Company’s common stock to employees, consultants and outside directors of the Company. On May 17, 2011, the 2010 Plan was amended to provide for the issuance of restricted stock units (“RSUs”) and on February 2, 2012, the 2010 Plan was amended to provide for the issuance of SSARs. Effective April 25, 2012 and May 23, 2017, the 2010 Plan was amended to increase the maximum number of shares of common stock available for issuance to an aggregate of 4,500,000 shares and 8,500,000 shares respectively. The vesting period for awards granted under the 2010 Plan, is determined by the Compensation Committee of the Board of Directors. The Compensation Committee also determines the expiration date of each equity award, however, stock options and SSARs may not be exercisable more than ten years after the date of grant as the maximum term of equity awards issued under the 2010 Plan is ten years. For the years ended December 31, 2017 , 2016 and 2015 , the Company recorded stock-based compensation expense, including stock options, SSARs, RSUs and certain warrant amortization, of approximately $1.1 million , $0.8 million and $1.6 million , respectively. Stock Options Stock option awards provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. The fair value of options granted is estimated at the date of grant. Expected volatility has been estimated using a combination of the historical volatility of the Company's common stock and the historical volatility of a group of comparable companies’ common stock, both using historical periods equivalent to the options’ expected lives. The expected dividend yield assumption is based on the Company’s intent not to issue a dividend in the foreseeable future. The risk-free interest rate assumption is based upon observed interest rates for securities with maturities approximating the options’ expected lives. The expected life was estimated based on historical experience and expectation of employee exercise behavior in the future giving consideration to the contractual terms of the award. A summary of the Company’s stock option activity is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2017 1,709,967 $ 4.76 Granted 25,000 3.50 Exercised (33,870 ) 2.64 Canceled/Expired (638,630 ) 3.75 Outstanding at December 31, 2017 1,062,467 $ 5.42 1.81 $ 1,240 Vested and expected to vest at December 31, 2017 1,062,467 $ 5.42 1.81 $ 1,240 Exercisable at December 31, 2017 962,467 $ 5.72 1.91 $ 1,004 As of December 31, 2017 , there is no remaining unrecognized stock-based compensation cost related to stock options expected to be recognized. The total fair value of vested stock options was approximately $73,000 , $0 and $0 for the years ended December 31, 2017 , 2016 and 2015 , respectively. The total intrinsic value of stock options exercised was approximately $65,000 , $0 and $5,900 for the years ended December 31, 2017 , 2016 and 2015 , respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option. As of December 31, 2017 and 2016 , 100,000 and 200,000 , respectively, of the Company’s outstanding options were subject to specific performance conditions consisting of regulatory approval of our lead drug candidate. Stock Appreciation Rights SSARs provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. Upon exercise, the gain, or intrinsic value, is settled by the delivery of SIGA stock to the employee. There were no SSARs granted during the years ended December 31, 2017 or 2016. During the year ended December 31, 2012, the Company granted 1.4 million shares of SSARs at a weighted average grant-date fair value of $0.68 per share. The exercise price of a SSAR is equal to the closing market price on the date of grant. The granted SSARs vested in equal annual installments over a period of three years and expire no later than seven years from the date of grant. Moreover, the appreciation of each SSAR was capped at a determined maximum value. At December 31, 2017 and 2016 , due to the cap on value the maximum number of shares that could be issued in the future was 162,393 and 360,031 , respectively. The fair value of granted SSARs has been estimated utilizing a Monte Carlo method. The Monte Carlo method is a statistical simulation technique used to provide the grant-date fair value of an award. As the issued SSARs were capped at maximum values, such attribute was considered in the simulation. The Company calculates the expected volatility using a combination of historical volatility of SIGA's common stock and the volatility of a group of comparable companies' common stock. The expected life from grant date was estimated based on the expectation of exercise behavior in consideration of the maximum value and contractual term of the SSARs. The dividend yield assumption is based on the Company’s intent not to issue a dividend in the foreseeable future. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the SSARs. A summary of the Company’s SSAR activity is as follows: Number of SSARs Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2017 1,183,024 $ 3.53 Granted — — Exercised (916,874 ) 3.53 Canceled/Expired — — Outstanding at December 31, 2017 266,150 $ 3.53 1.09 $ 351 Vested and expected to vest at December 31, 2017 266,150 $ 3.53 1.09 $ 351 Exercisable at December 31, 2017 266,150 $ 3.53 1.09 $ 351 The total intrinsic value of SSARs exercised was approximately $0.9 million for the year ended December 31, 2017. For the years ended December 31, 2016 and 2015 there were no SSARs exercised. Restricted Stock Awards/Restricted Stock Units RSUs awarded to employees vest in equal annual installments over a three-year period and RSUs awarded to directors of the Company vest over a one-year period. A summary of the Company’s RSU activity is as follows: Number of RSUs Weighted Average Grant-Date Fair Value Outstanding at January 1, 2017 1,455,689 $ 2.36 Granted 289,648 3.51 Vested and released (273,335 ) 2.21 Canceled/Expired — — Outstanding at December 31, 2017 (1) 1,472,002 $ 2.61 (1) Included 394,118 restricted stock units that have vested but have not converted into common stock. As of December 31, 2017 , $ 1.1 million of total remaining unrecognized stock-based compensation cost related to RSUs is expected to be recognized over the weighted-average remaining requisite service period of 1.77 years. The weighted average fair value at the date of grant for restricted stock awards granted during the years ended December 31, 2017 , 2016 and 2015 was $3.51 , $2.24 and $2.00 per share, respectively. Based on the grant date, the total fair value of restricted stock and restricted stock units vested and released during the years ended December 31, 2017 , 2016 and 2015 was approximately $0.6 million , $1.4 million and $1.8 million , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017 the U.S. government enacted comprehensive tax reform commonly referred to as the Tax Cuts and Jobs Act (“TCJA”). Under FASB Accounting Standards Codification (“ASC 740”), the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The TCJA makes broad and complex changes to the U.S. tax code, including, but not limited to: (1) reducing the U.S. federal corporate tax rate from 35% to 21% ; (2) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; (3) bonus depreciation that will allow for full expensing of qualified property; (4) creating a new limitation on deductible interest expense; (5) eliminating the corporate alternative minimum tax ("AMT"); (6) limitation on the deductibility of executive compensation under Internal Revenue Code §162(m); and (7) new tax rules related to foreign operations. On December 22, the SEC staff issued Staff Accounting Bulletin (“SAB”) No. 118, which provides guidance on accounting for the tax effects of TCJA. The purpose of SAB No. 118 was to address any uncertainty or diversity of view in applying ASC Topic 740, Income Taxes in the reporting period in which the TCJA was enacted. SAB No. 118 addresses situations where the accounting is incomplete for certain income tax effects of the TJCA upon issuance of a company’s financial statements for the reporting period that includes the enactment date. SAB No. 118 allows for a provisional amount to be recorded if it is a reasonable estimate of the impact of the TCJA. Additionally, SAB No. 118 allows for a measurement period to finalize the impacts of the TCJA, not to extend beyond one year from the date of enactment. In connection with the initial analysis of the impact of the TCJA, the Company has recorded a provisional decrease in our deferred tax assets and liabilities with a corresponding adjustment to the related valuation allowance. In addition, the Company recorded an income tax benefit of $2.7 million related to the elimination of the AMT as such amounts will be refundable, in cash, under TCJA. The Company expects to collect the refund no later than 2021. The estimated refundable AMT credit is included in deferred tax assets as of December 31, 2017. While the Company is able to make a reasonable estimate of the impact of the reduction in the corporate rate, such estimate is subject to further analysis, interpretation and clarification of the TCJA, which could result in changes to this estimate during 2018. The Company's (benefit) provision for income taxes comprises the following: For the year ended December 31, 2017 2016 2015 Current: Federal $ 623,060 $ (5,093 ) $ 439,934 State and local 1,179 (1,446 ) 946 Total current provision (benefit) 624,239 (6,539 ) 440,880 Deferred: Federal (2,724,371 ) 21,252 19,006 State and local 6,342 (829 ) 2,097 Total deferred (benefit) provision (2,718,029 ) 20,423 21,103 Total (benefit) provision $ (2,093,790 ) $ 13,884 $ 461,983 The Company’s deferred tax assets and liabilities comprise the following: As of December 31, 2017 2016 Deferred income tax assets: Net operating losses $ 38,087,782 $ 72,726,440 Deferred research and development costs 205,527 669,602 Amortization of intangible assets 282,213 665,531 Share-based compensation 1,001,662 1,687,243 Fixed assets 417,085 667,008 Deferred revenue 84,130,212 102,520,433 Alternative minimum tax credits 2,652,250 2,029,190 Other 1,024,082 1,337,941 Deferred income tax assets 127,800,813 182,303,388 Less: valuation allowance (102,556,657 ) (155,465,173 ) Deferred income tax assets, net of valuation allowance $ 25,244,156 $ 26,838,215 Deferred income tax liabilities: Amortization of goodwill (193,458 ) (287,729 ) Capitalized contract costs (21,518,646 ) (25,854,435 ) Other (1,100,089 ) (982,117 ) Deferred income tax asset (liability), net $ 2,431,963 $ (286,066 ) The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which is inherently uncertain. The Company assesses all available positive and negative evidence to determine if its existing deferred tax assets are realizable on a more-likely-than-not basis. In making such assessment, the Company considered the reversal of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operating results. The ultimate realization of a deferred tax asset is ultimately dependent on the Company's generation of sufficient taxable income within the available net operating loss carryback and/or carryforward periods to utilize the deductible temporary differences. Based on the weight of available evidence including three-year cumulative pre-tax losses, the Company continued to conclude that its deferred tax assets are not realizable on a more-likely-than-not basis and that a full valuation allowance is required with the exception of its alternative minimum tax carryforward that is refundable as a result of TCJA. The valuation allowance decreased by $53.0 million from December 31, 2016. The decrease is primarily related to the re-measurement of deferred tax assets and liabilities using the new U.S. federal statutory rate of 21% . As of December 31, 2017 , the Company had $174.3 million of federal net operating loss carryforwards, which expire in 2034 to 2036, to offset future taxable income. The Company’s effective tax rate differs from the U.S. federal statutory income tax rate as follows: As of December 31, 2017 2016 2015 Statutory federal income tax rate (35.0 )% (35.0 )% (35.0 )% State tax benefit (3.9 )% 0.6 % — % Increase in fair value of common stock warrants 4.3 % 0.8 % — % Reorganization costs — % 3.3 % 7.0 % Other (1.8 )% 0.2 % 1.4 % U.S. federal tax law change (5.1 )% — % — % Valuation allowance on deferred tax assets 36.0 % 30.1 % 27.8 % Effective tax rate (5.5 )% — % 1.2 % For the year ended December 31, 2017 and December 31, 2016 , the Company’s effective tax rate differs from the statutory rate principally due to operating losses for which no tax benefit was provided, coupled with the impact of the TCJA. For the year ended December 31, 2015 , the Company's effective tax rate differs from the statutory rate principally due to the operating losses for which no tax benefit was provided and non-deductible reorganization expenses. The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2017 and 2016 , the Company has no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months from December 31, 2017 . The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The open tax years for U.S. federal, state and local tax returns are 2013-2017; open tax years relating to any of the company’s net operating losses begin in 2001. In the event that the Company concludes that it is subject to interest and/or penalties arising from uncertain tax positions, the Company will present interest and penalties as a component of income taxes. No amounts of interest or penalties were recognized in the Company’s consolidated financial statements for each of the years in the three-year period ended December 31, 2017 .

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating lease commitments The Company leases its Corvallis, Oregon, facilities and office space under an operating lease which was signed on November 3, 2017 and commenced on January 1, 2018. This lease expires December 31, 2019. The Company had a lease for the same location prior to this lease. On May 26, 2017 the Company and M&F Incorporated entered into a ten-year office lease agreement (the “New HQ Lease”), pursuant to which the Company agreed to lease 3,200 square feet at 27 East 62 nd Street, New York, New York. The Company is utilizing premises leased under the New HQ Lease as its new corporate headquarters. Rental expense, including charges for maintenance, utilities, real estate taxes and other operating expenses, totaled $1.0 million , $1.2 million and $1.4 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Future minimum cash rental commitments under non-cancelable operating leases as of December 31, 2017 are expected to be as follows: 2018 $ 571,705 2019 596,237 2020 347,259 2021 349,422 2020 368,467 Thereafter 1,788,749 Total $ 4,021,839 Legal Proceedings After several years of proceedings in litigation initiated by PharmAthene in 2006, the Delaware Court of Chancery on August 8, 2014 issued an opinion and order in which it determined, among other things, that PharmAthene was entitled to a lump sum damages award for its lost profits including interest and fees, based on U.S. government purchases of the Company's smallpox drug allegedly anticipated as of December 2006. On September 16, 2014, as a consequence of SIGA’s chapter 11 filing, the legal proceedings with PharmAthene were stayed (see Note 1 ), except that the parties agreed by stipulation approved by the Court on October 8, 2014 that the litigation could proceed. On January 15, 2015, the Delaware Court of Chancery entered its Final Order and Judgment (the “Final Order and Judgment”) awarding PharmAthene approximately $195.0 million , including pre-judgment interest up to January 15, 2015 (the “Judgment”). On December 23, 2015 the Delaware Supreme Court affirmed the Judgment. Pursuant to the Final Order and Judgment, SIGA also was liable to PharmAthene for $30,663.89 per day in post-judgment interest. On a series of dates up to and including a final payment on November 16, 2016, the Company paid PharmAthene an aggregate of $217.0 million to fully satisfy the Judgment, including post-judgment interest, in accordance with the bankruptcy plan of reorganization. From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Board of Directors and Outside Counsel A member of the Company’s Board of Directors is a member of the Company’s outside counsel. During the years ended December 31, 2017, 2016 and 2015, the Company incurred expenses of $400,000 , $1.5 million and $602,000 , respectively, related to services provided by the outside counsel. On December 31, 2017 the Company’s outstanding payables and accrued expenses included a $35,000 liability to the outside counsel. Rights Offering-Backstop Agreement On October 13, 2016, in connection with the Rights Offering as discussed above, the Company entered into the Backstop Agreement with an affiliate of M&F (M&F is a principal stockholder of the Company) and the other Backstop Parties. Under the terms of the Backstop Agreement, the Backstop Parties agreed to purchase, pursuant to a separate private placement, a number of shares of common stock equal to the numbers of shares that would have not been subscribed for in the Rights Offering. The Backstop Agreement provided that the subscription price for the Backstop Parties would be equal to the subscription price applicable to all shareholders under the Rights Offering. Because the Rights Offering was fully subscribed, the Backstop Parties were not required to draw on such commitment. The Company issued 708.530 shares to Backstop Parties, of which approximately 565,000 shares were received by M&F, in payment of the five percent backstop fee ( $1,764,240 ) payable to the Backstop Parties in connection with the backstop agreement. When shares were issued to the Backstop Parties in payment of the backstop fee, the stock price of SIGA common stock was $2.49 per share (the closing price of the Company’s common stock on November 16, 2016). The fair value of the shares issued in satisfaction of the backstop fee was expensed to the income statement in 2016. There are no remaining payment obligations to the Backstop Parties under the Backstop Agreement. Real Estate Leases On May 26, 2017 the Company and M&F Incorporated entered into the New HQ Lease, pursuant to which the Company agreed to lease 3,200 square feet at 27 East 62 nd Street, New York, New York. The Company is utilizing premises leased under the New HQ Lease as its new corporate headquarters. The Company's rental obligations consist of a fixed rent of $25,333 , per month in the first sixty-three months of the term, subject to a rent abatement for the first six months of the term. From the first day of the sixty-fourth month of the term through the expiration or earlier termination of the lease, the Company's rental obligations consist of a fixed rent of $29,333 per month. In addition to the fixed rent, the Company will pay a facility fee in consideration of the landlord making available certain ancillary services, commencing on the first anniversary of entry into the lease. The facility fee will be $3,333 per month for the second year of the term and increase by five percent each year thereafter, to $4,925 per month in the final year of the term. On July 31, 2017, the Company and M&F, entered into a Termination of Sublease Agreement (the “Old HQ Sublease Termination Agreement”), pursuant to which the Company and M&F agreed to terminate the sublease dated January 9, 2013 for 6,676 square feet of rental square footage located at 660 Madison Avenue, Suite 1700, New York, New York (such sublease being the “ Old HQ Sublease ” and the location being the “ Old HQ ” ). Effectiveness of the Old HQ Sublease Termination Agreement was conditioned upon the commencement of a sublease for the Old HQ between M&F and a new subtenant (the “Replacement M&F Sublease”), which occurred on August 2, 2017. The Old HQ Sublease Termination Agreement obligates the Company to pay, on a monthly basis, an amount equal to the discrepancy (the “Rent Discrepancy”) between the sum of fixed rent and Additional Rent (as defined below) under the Old HQ Overlease (as defined below) and the sum of fixed rent and Additional Rent under the Replacement M&F Sublease. Under the Old HQ Sublease Termination Agreement, the Company and M&F release each other from any liability under the Old HQ Sublease. Under the Old HQ Sublease, the Company was obligated to pay fixed rent of approximately $60,000 per month until August 2018 and approximately $63,400 per month thereafter until the Old HQ Sublease expiration date of August 31, 2020. Additionally, the Company was obligated to pay certain operating expenses and taxes (“Additional Rent”), such Additional Rent being specified in the overlease between M&F and the landlord at 660 Madison Avenue (the “Old HQ Overlease”). Under the Replacement M&F Sublease, the subtenant’s rental obligations were excused for the first two ( 2 ) months of the lease term (“Rent Concession Period ” ). Thereafter, the subtenant is obligated to pay fixed rent of $36,996 per month for the first twelve ( 12 ) months, $37,831 per month for the next 12 months, and $38,665 per month until the scheduled expiration of the Replacement M&F Sublease on August 24, 2020. In addition to fixed rent, the subtenant is also obligated to pay, pursuant to the Replacement M&F Sublease, a portion of the Additional Rent specified in the Old HQ Overlease. For the time period between August 2, 2017 and August 31, 2020 (the expiration date of the Old HQ Sublease), the Company estimates that it will pay a total of approximately $0.9 million combined in fixed rent and additional amounts payable under the New HQ Lease and a total of approximately $1.1 million in Rent Discrepancy under the Old HQ Sublease Termination Agreement, for a cumulative total of $2.0 million . In contrast, fixed rent and estimated Additional Rent under the Old HQ Sublease, for the aforementioned time period, would have been a total of approximately $2.4 million if each of the New HQ Lease, Replacement M&F Sublease and Old HQ Sublease Termination Agreement had not been entered into by each of the parties thereto. Because amounts such as operating expenses and taxes may vary, the foregoing totals can only be estimated at this time and are subject to change. As a result of the above-mentioned transactions, the Company has discontinued usage of Old HQ in the third quarter of 2017. As such, for the year ended December 31, 2017 the Company recorded a loss of approximately $1.1 million in accordance with ASC 420 Exit or Disposal Obligations . This loss primarily represented the discounted value of estimated Rent Discrepancy payments to occur in the future, and included costs related to the termination of the old HQ Sublease. The Company also wrote-off approximately $0.1 million of leasehold improvements and furniture and fixtures related to the Old HQ. The following table summarizes activity relating to the liability that was recorded as a result of the lease termination: Lease Termination Liability Balance at December 31, 2016 $ — Charges 1,096,648 Cash payments (282,026 ) Balance at December 31, 2017 $ 814,622

Reorganization (Notes)

Reorganization (Notes)	12 Months Ended
	Dec. 31, 2017
Reorganizations [Abstract]
Reorganization	Reorganization Items, net: Reorganization items represent expenses in connection with the chapter 11 case. For the years ended December 31, 2016 and 2015, reorganization items consisted of the following: December 31, 2016 December 31, 2015 Legal fees $ 1,951,381 $ 5,719,052 Professional fees 1,732,521 2,027,827 Trustee fees 33,000 59,000 Other — $ 5,672 Total $ 3,716,902 $ 7,811,551 Subsequent to the Effective Date of the Plan, expenses directly attributable to the implementation of the Plan are reported in selling, general and administrative expenses. During the years ended December 31, 2016 and 2015, the Company paid approximately $4.6 million and $6.7 million , respectively, for reorganization items.

Financial Information By Quarte

Financial Information By Quarter (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information [Abstract]
Financial Information By Quarter	Financial Information By Quarter (Unaudited) Three Months Ended 2017 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues $ 5,202 $ 4,265 $ 1,390 $ 1,412 Selling, general and administrative 2,870 3,058 3,094 3,281 Research and development 6,360 5,068 2,471 2,781 Patent expenses 241 197 251 221 Lease termination — — 1,225 — Operating loss (4,269 ) (4,059 ) (5,651 ) (4,871 ) Net loss (8,615 ) (7,501 ) (9,816 ) (10,303 ) Loss per common share: basic and diluted $ (0.11 ) $ (0.10 ) $ (0.12 ) $ (0.13 ) Three Months Ended 2016 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues $ 1,270 $ 1,901 $ 4,658 $ 7,159 Selling, general and administrative 2,656 3,739 2,855 4,464 Research and development 2,536 2,948 6,069 8,158 Patent expenses 220 240 230 219 Interest on PharmAthene liability 2,917 4,259 3,566 927 Operating loss (7,059 ) (9,285 ) (8,062 ) (6,609 ) Net loss (10,449 ) (9,566 ) (9,244 ) (10,439 ) Loss per common share: basic and diluted $ (0.19 ) $ (0.18 ) $ (0.17 ) $ (0.15 )

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The consolidated financial statements and related disclosures are prepared in conformity with accounting principles generally accepted in the United States of America. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the periods reported. The most significant estimates include the variables used in the calculation of fair value of stock-based awards and warrants granted or issued by the Company; reported amounts of revenue; and the realization of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
Basis of Presentation	Basis of Presentation The consolidated financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
Restricted Cash and Cash Equivalents	Restricted Cash and Cash Equivalents A portion of the Company’s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for $5 million , cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned $5 million in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. As of December 31, 2017, the restricted cash balance was $17.2 million of which $10.7 million is designated as a current asset and the remainder is designated as non-current. See Note 7 for additional information
Concentration of Credit Risk	Concentration of Credit Risk The Company has cash in bank accounts that exceed the Federal Deposit Insurance Corporation insured limits. The Company has not experienced any losses on its cash accounts and no allowance has been provided for potential credit losses because management believes that any such losses would be minimal, if any.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2017 and 2016 , 100% of accounts receivables represented receivables from Biomedical Advanced Research and Development Authority (“BARDA”) and National Institutes of Health (“NIH”). An allowance for doubtful accounts is based on specific analysis of the receivables. At December 31, 2017 and 2016 , the Company had no allowance for doubtful accounts.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may expire prior to expected sale or has a cost basis in excess of its net realizable value. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such unmarketable inventory to its net realizable value.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five years for laboratory equipment; three years for computer equipment; and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance, repairs and minor replacements are charged to expense as incurred.
Warrant Liability	Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities.
Revenue Recognition	Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, collectability is reasonably assured, title and risk of loss have been transferred to the customer and there are no further contractual obligations. Certain arrangements may provide for multiple deliverables, in which there may be a combination of: up-front licenses; research, development, regulatory or other services; and delivery of product. Multiple deliverable arrangements can be divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (i) the delivered item(s) have value to the customer on a standalone basis and (ii) in circumstances in which an arrangement includes a general right of return with respect to delivered items, then performance of the remaining deliverables must be considered probable and substantially in control of the Company. If multiple deliverables cannot be divided into separate units of accounting then the deliverables must be combined into a single unit of accounting. Total consideration in a multiple deliverable arrangement is allocated to units of accounting on a relative fair value of selling price basis. Consideration allocated to a delivered item or unit of accounting is limited to the amount that is not contingent upon delivery of additional items. Direct costs incurred by the Company and associated with the deferral of revenue for a unit of accounting are also deferred and are recognized as expenses in the same period that the related deferred revenue is recognized as revenue. Subject to the above, payments for development activities are recognized as revenue when earned, over the period of effort. Funding for the acquisition of capital assets under cost-plus-fee contracts or grants is evaluated for appropriate recognition as a reduction to the cost of the asset, a financing arrangement, or revenue based on the specific terms of the related grant or contract. For the years ended December 31, 2017 , 2016 , and 2015 , revenues from BARDA and NIH were 100% of total revenues recognized by the Company.
Research and Development	Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to the BARDA Contract, including employee related costs, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no alternative future uses, are expensed as incurred.
Goodwill	Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value.
Share-based Compensation	Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value was estimated using the Black-Scholes model and for stock-settled stock appreciation rights (“SSARs”), fair value was estimated using the Monte Carlo method. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods in the Company’s consolidated statement of operations. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates.
Income Taxes	Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not that some or the entire deferred tax asset will not be realized. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain.
Net Loss per Share	Net Loss per Share The objective of basic earnings per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 – Quoted prices for identical instruments in active markets. • Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. • Level 3 – Instruments where significant value drivers are unobservable to third parties. The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of common stock warrants on a recurring basis and classify such liability-classified warrants in Level 3. As described in Note 8 , the fair value of the liability-classified warrant was $11.5 million at December 31, 2017 . At December 31, 2017 , the fair value of the debt was $74.1 million and the carrying value of the debt was $71.0 million . The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement. The fair value of the loan was measured using Level 3 inputs. The discount rate was determined using market participant assumptions. There were no transfers between levels of the fair value hierarchy during 2017.
Legal Contingencies	Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Segment Reporting	Segment Information The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer, who is the Chief Operating Decision Maker. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and has only one reportable segment.
Revision	Revision In connection with the preparation of the consolidated financial statements for the year ended December 31, 2017, the Company identified that its warrant liability was incorrectly classified as a current liability on the December 31, 2016 balance sheet. The 2016 balance sheet has been revised to properly classify the warrant liability as a long-term liability. This revision does not impact the consolidated statement of operations and comprehensive loss, the consolidated statement of cash flows or the consolidated statement of changes in stockholders’ deficiency for the year ended December 31, 2016 and is not considered material to the previously issued consolidated financial statements or the current consolidated financial statements for the year ended December 31, 2017 as a whole.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) . The amendments in Part I of this ASU change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of this ASU recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company has elected to early adopt ASU No. 2017-11. which retained the liability classification of the Company's warrant and had no impact on the Company's consolidated financial statements. On May 10, 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718)-Scope of Modification Accounting . The guidance clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for financial statements issued for fiscal years beginning after December 13, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company believes the adoption of ASU No. 2017-09 will not have a significant impact on its consolidated financial statements. On January 26, 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. The same one-step impairment test will be applied to goodwill at all reporting units, even those with zero or negative carrying amounts. The revised guidance will be applied prospectively, and is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company believes the adoption of ASU No. 2017-04 will not have a significant impact on its consolidated financial statements. On November 17, 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force . The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The guidance requires application using a retrospective transition method. The Company believes the adoption of ASU No. 2016-18 will have a significant impact due to the fact the Company will reflect sources and uses of restricted cash in the consolidated statement of cash flows and provide a reconciliation of restricted cash balances. On August 26, 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), a consensus of the FASB’s Emerging Issues Task Force . The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company believes the adoption of ASU No. 2016-15 will not have a significant impact on its consolidated financial statements. In March 2016, the FASB amended the existing accounting standards for stock-based compensation, ASU No. 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments impact several aspects of accounting for share-based payment transactions, including the income tax consequences, expected forfeitures, classification of awards as either equity or liabilities, and classification in the statement of cash flows. The Company adopted the amendments in the first quarter of 2017. Prior to adoption of ASU No. 2016-09, tax attributes related to stock option windfall deductions were not recorded until they resulted in a reduction of cash tax payable. As of December 31, 2016, the excluded windfall deductions for federal and state purposes were $1.6 million . Upon adoption of ASU No. 2016-09, the Company recognized the excluded windfall deductions as a deferred tax asset with a corresponding offset to the valuation allowance. With regard to the forfeiture policy election, we will continue to estimate the number of awards expected to be forfeited. On February 25, 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842) , which relates to the accounting for leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-02 will have on its consolidated financial statements. The Company expects its real estate leases to be capitalized on its balance sheet. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition-Construction-Type and Production-Type Contracts. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim periods beginning after December 15, 2016. The Company will adopt this standard in the first quarter of 2018 using the modified retrospective method, which will not change any of the historical financial results previously reported by the Company. Any adjustment upon adoption will be recorded as an accumulated adjustment due to a change in accounting in the stockholders' deficiency section of the Company's consolidated balance sheet. The Company has determined that revenue connected with courses of TPOXX ® delivered to BARDA and related services, milestones and advance payments (activities in combination that constitute one performance obligation) will be recognized at a point in time when the constraint on revenue (quantification, and specification, of any possible replacement obligation) has been resolved. Currently, the revenue constraint is not expected to be resolved prior to adoption of this standard. As such, the Company does not expect adoption of this standard to have an impact on the timing of revenue recognition for the above-mentioned activities. Separately, the Company has determined that revenue for performance obligations associated with R&D activities will be recognized over time similar in manner to the Company’s historical approach. As a result, the Company believes the adoption of ASU No.2014-09 will not have a significant impact on its consolidated financial statements.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company incurred losses for the years ended December 31, 2017 , 2016 and 2015 . For all periods presented, all equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of: Year Ended December 31, 2017 2016 2015 Stock Options 1,386,176 1,789,751 2,047,083 Stock-Settled Stock Appreciation Rights (“SSAR”) 333,252 360,031 368,331 Restricted Stock Units 1,396,730 705,850 700,265 Warrants 2,690,950 877,303 82,192
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs: Fair Value Measurements of Level 3 liability classified warrant Warrant liability at December 31, 2016 $ 6,727,409 Increase in fair value of warrant liability 4,738,753 Warrant liability at December 31, 2017 $ 11,466,162

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	Inventory consisted of the following: As of December 31, 2017 December 31, 2016 Work in-process $ 2,025,445 $ 18,916,084 Finished goods 957,804 7,293,880 Inventory $ 2,983,249 $ 26,209,964

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment consisted of the following: As of December 31, 2017 December 31, 2016 Leasehold improvements $ 2,420,028 $ 2,542,044 Computer equipment 701,762 770,479 Furniture and fixtures 363,588 455,220 3,485,378 3,767,743 Less-accumulated depreciation (3,346,738 ) (3,468,266 ) Property, plant and equipment, net $ 138,640 $ 299,477

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses and other current liabilities consisted of the following: As of December 31, 2017 December 31, 2016 Bonus $ 2,538,340 $ 2,357,194 Deferred revenue-R&D for TPOXX ® intravenous formulation 1,255,318 — Professional fees 381,980 481,641 Vacation 328,588 262,664 Other 977,353 1,483,253 Accrued expenses and other current liabilities $ 5,481,579 $ 4,584,752

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock options activity	A summary of the Company’s stock option activity is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2017 1,709,967 $ 4.76 Granted 25,000 3.50 Exercised (33,870 ) 2.64 Canceled/Expired (638,630 ) 3.75 Outstanding at December 31, 2017 1,062,467 $ 5.42 1.81 $ 1,240 Vested and expected to vest at December 31, 2017 1,062,467 $ 5.42 1.81 $ 1,240 Exercisable at December 31, 2017 962,467 $ 5.72 1.91 $ 1,004
Stock appreciation rights award activity	A summary of the Company’s SSAR activity is as follows: Number of SSARs Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2017 1,183,024 $ 3.53 Granted — — Exercised (916,874 ) 3.53 Canceled/Expired — — Outstanding at December 31, 2017 266,150 $ 3.53 1.09 $ 351 Vested and expected to vest at December 31, 2017 266,150 $ 3.53 1.09 $ 351 Exercisable at December 31, 2017 266,150 $ 3.53 1.09 $ 351
Restricted stock and restricted stock units activity	RSUs awarded to employees vest in equal annual installments over a three-year period and RSUs awarded to directors of the Company vest over a one-year period. A summary of the Company’s RSU activity is as follows: Number of RSUs Weighted Average Grant-Date Fair Value Outstanding at January 1, 2017 1,455,689 $ 2.36 Granted 289,648 3.51 Vested and released (273,335 ) 2.21 Canceled/Expired — — Outstanding at December 31, 2017 (1) 1,472,002 $ 2.61 (1) Included 394,118 restricted stock units that have vested but have not converted into common stock.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense (benefit)	he Company's (benefit) provision for income taxes comprises the following: For the year ended December 31, 2017 2016 2015 Current: Federal $ 623,060 $ (5,093 ) $ 439,934 State and local 1,179 (1,446 ) 946 Total current provision (benefit) 624,239 (6,539 ) 440,880 Deferred: Federal (2,724,371 ) 21,252 19,006 State and local 6,342 (829 ) 2,097 Total deferred (benefit) provision (2,718,029 ) 20,423 21,103 Total (benefit) provision $ (2,093,790 ) $ 13,884 $ 461,983
Schedule of deferred tax assets and liabilities	he Company’s deferred tax assets and liabilities comprise the following: As of December 31, 2017 2016 Deferred income tax assets: Net operating losses $ 38,087,782 $ 72,726,440 Deferred research and development costs 205,527 669,602 Amortization of intangible assets 282,213 665,531 Share-based compensation 1,001,662 1,687,243 Fixed assets 417,085 667,008 Deferred revenue 84,130,212 102,520,433 Alternative minimum tax credits 2,652,250 2,029,190 Other 1,024,082 1,337,941 Deferred income tax assets 127,800,813 182,303,388 Less: valuation allowance (102,556,657 ) (155,465,173 ) Deferred income tax assets, net of valuation allowance $ 25,244,156 $ 26,838,215 Deferred income tax liabilities: Amortization of goodwill (193,458 ) (287,729 ) Capitalized contract costs (21,518,646 ) (25,854,435 ) Other (1,100,089 ) (982,117 ) Deferred income tax asset (liability), net $ 2,431,963 $ (286,066 )
Schedule of effective income tax rate reconciliation	The Company’s effective tax rate differs from the U.S. federal statutory income tax rate as follows: As of December 31, 2017 2016 2015 Statutory federal income tax rate (35.0 )% (35.0 )% (35.0 )% State tax benefit (3.9 )% 0.6 % — % Increase in fair value of common stock warrants 4.3 % 0.8 % — % Reorganization costs — % 3.3 % 7.0 % Other (1.8 )% 0.2 % 1.4 % U.S. federal tax law change (5.1 )% — % — % Valuation allowance on deferred tax assets 36.0 % 30.1 % 27.8 % Effective tax rate (5.5 )% — % 1.2 %

Commitments and Contingencies O

Commitments and Contingencies Operating Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum cash rental commitments under non-cancelable operating leases as of December 31, 2017 are expected to be as follows: 2018 $ 571,705 2019 596,237 2020 347,259 2021 349,422 2020 368,467 Thereafter 1,788,749 Total $ 4,021,839

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following table summarizes activity relating to the liability that was recorded as a result of the lease termination: Lease Termination Liability Balance at December 31, 2016 $ — Charges 1,096,648 Cash payments (282,026 ) Balance at December 31, 2017 $ 814,622

Reorganization (Tables)

Reorganization (Tables)	12 Months Ended
	Dec. 31, 2017
Reorganizations [Abstract]
Reorganization items	, reorganization items consisted of the following: December 31, 2016 December 31, 2015 Legal fees $ 1,951,381 $ 5,719,052 Professional fees 1,732,521 2,027,827 Trustee fees 33,000 59,000 Other — $ 5,672 Total $ 3,716,902 $ 7,811,551

Financial Information By Quar32

Financial Information By Quarter (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information [Abstract]
Schedule of quarterly financial information	Financial Information By Quarter (Unaudited) Three Months Ended 2017 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues $ 5,202 $ 4,265 $ 1,390 $ 1,412 Selling, general and administrative 2,870 3,058 3,094 3,281 Research and development 6,360 5,068 2,471 2,781 Patent expenses 241 197 251 221 Lease termination — — 1,225 — Operating loss (4,269 ) (4,059 ) (5,651 ) (4,871 ) Net loss (8,615 ) (7,501 ) (9,816 ) (10,303 ) Loss per common share: basic and diluted $ (0.11 ) $ (0.10 ) $ (0.12 ) $ (0.13 ) Three Months Ended 2016 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues $ 1,270 $ 1,901 $ 4,658 $ 7,159 Selling, general and administrative 2,656 3,739 2,855 4,464 Research and development 2,536 2,948 6,069 8,158 Patent expenses 220 240 230 219 Interest on PharmAthene liability 2,917 4,259 3,566 927 Operating loss (7,059 ) (9,285 ) (8,062 ) (6,609 ) Net loss (10,449 ) (9,566 ) (9,244 ) (10,439 ) Loss per common share: basic and diluted $ (0.19 ) $ (0.18 ) $ (0.17 ) $ (0.15 )

Organization and Basis of Pre33

Organization and Basis of Presentation Liquidity (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2016
Procurement Contract [Line Items]
Reduced holdback amount		$ 40.9
Scenario, Forecast | BARDA Contract
Procurement Contract [Line Items]
Reduced holdback amount	$ 41

Organization and Basis of Pre34

Organization and Basis of Presentation Plan of Reorganization (Details) $ in Millions	Dec. 22, 2016USD ($)
Organization and Basis of Presentation [Abstract]
Payments for legal settlements	$ 217

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Restricted Cash and Cash Equivalents) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		$ 17,200,000
Restricted cash, short-term		$ 10,701,305	$ 10,138,890
Secured Debt | Scenario, Forecast | Loan Agreement
Restricted Cash and Cash Equivalents Items [Line Items]
Additional borrowing capacity	$ 5,000,000

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Accounts Receivable, Property, Plant and Equipment, and Net Loss Per Share) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Property, Plant and Equipment [Line Items]
Receivables percentage	100.00%
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Accounting Standards Update 2016-09
Property, Plant and Equipment [Line Items]
Deferred income tax assets, net	$ 1.6

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Revenue) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Accounting Policies [Abstract]
Revenue, percentage	100.00%	100.00%	100.00%

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Anti-dilutive Securities Exluded from Calculation of Diluted Loss per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	1,386,176	1,789,751	2,047,083
Stock Appreciation Rights (SARs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	333,252	360,031	368,331
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	1,396,730	705,850	700,265
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	2,690,950	877,303	82,192

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Fair Value of Financial Instruments) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Sep. 02, 2016
Class of Warrant or Right [Line Items]
Fair value of warrant	$ 11,466,162	$ 6,727,409
Warrants
Class of Warrant or Right [Line Items]
Fair value of warrant	11,500,000		$ 5,800,000
Senior Secured Term Loan
Class of Warrant or Right [Line Items]
Loan outstanding	71,000,000
Senior Secured Term Loan | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Class of Warrant or Right [Line Items]
Loan outstanding	$ 74,100,000

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Change in Level 3 Liability) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Accounting Policies [Abstract]
Warrant liability at December 31, 2016	$ 6,727,409
Increase in fair value of warrant liability	4,738,753
Warrant liability at December 31, 2017	$ 11,466,162

Procurement Contract and Rese41

Procurement Contract and Research Agreements (Details)	Jun. 24, 2011course	May 13, 2011USD ($)course	May 31, 2011course	Dec. 31, 2017USD ($)	Dec. 31, 2017USD ($)course	Dec. 31, 2016USD ($)course	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)
Procurement Contract [Line Items]
Reduced holdback amount						$ 40,900,000
Contract value of various options		$ 122,700,000
Amount of option to be received from BARDA for approval for extension of 84 moth expiry		50,000,000
Contract value, detail of option exercisable, development activities		58,300,000
Contract value, detail of option exercisable, production activities		14,400,000
Contract value, option, FDA approval		50,000,000
Deferred costs				$ 96,592,334	$ 96,592,334	72,649,277
Deferred Revenue				1,255,318	1,255,318	$ 0
Research and development revenue long-term contract					9,000,000
Research and development, future aggregate amount				12,900,000	12,900,000
BARDA Contract
Procurement Contract [Line Items]
Number of courses to be delivered | course			2,000,000
Value of contract		472,300,000
Contract value of manufacturing and delivery activities		$ 409,800,000			$ 40,900,000
Number of courses under modified contract | course	1,700,000	1,700,000
Contract value of development and support activities		$ 62,500,000
Government contract, number of free courses | course		300,000
Government contract, total number of courses required to be delivered | course					2,000,000	2,000,000
Proceeds from manufacture and physical delivery of course, government contractses				368,900,000	$ 368,900,000
Proceeds from advance payments under the BARDA contract									$ 41,000,000
Milestone payment				20,500,000			$ 8,200,000	$ 12,300,000
Proceeds from physical delivery of courses, government contracts							$ 286,900,000
Deferred costs				96,500,000	96,500,000	$ 72,200,000
Deferred Revenue				$ 377,600,000	$ 377,600,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Work in process	$ 2,025,445	$ 18,916,084
Finished goods	957,804	7,293,880
Inventory	$ 2,983,249	$ 26,209,964

Inventory - Narrative (Details)

Inventory - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory write-down	$ 536,000	$ 0	$ 0
Inventory write-downs	$ 686,000

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Leasehold improvements, gross	$ 2,420,028	$ 2,542,044
Computer equipment, gross	701,762	770,479
Furniture and fixtures, gross	363,588	455,220
Property, plant and equipment, gross	3,485,378	3,767,743
Accumulated depreciation, depletion and amortization, property, plant, and equipment	(3,346,738)	(3,468,266)
Property, plant and equipment, net	$ 138,640	$ 299,477

Property, Plant and Equipment45

Property, Plant and Equipment - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Inventory write-down	$ 536,000	$ 0	$ 0
Depreciation and other amortization	132,189	$ 174,275	$ 247,357
Leasehold Improvements and Furnitures and Fixtures
Property, Plant and Equipment [Line Items]
Inventory write-down	$ 129,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Bonus	$ 2,538,340	$ 2,357,194
Deferred Revenue	1,255,318	0
Professional fees	381,980	481,641
Vacation	328,588	262,664
Other	977,353	1,483,253
Accrued expenses and other current liabilities	$ 5,481,579	$ 4,584,752

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018	Dec. 31, 2016	Sep. 02, 2016
Debt Instrument [Line Items]
Fair value of warrant	$ 11,466,162	$ 11,466,162			$ 11,466,162		$ 6,727,409
London Interbank Offered Rate (LIBOR) | Loan Agreement
Debt Instrument [Line Items]
Margin for term loan					11.50%
Debt instrument, interest rate during period					18.80%
Warrants
Debt Instrument [Line Items]
Fair value of warrant	11,500,000	11,500,000			$ 11,500,000			$ 5,800,000
Secured Debt | Loan Agreement
Debt Instrument [Line Items]
Line of credit facility	80,000,000	80,000,000			80,000,000			80,000,000
Interest expense, debt					14,800,000
Interest paid on term loan					10,300,000
Amortization of debt issuance costs	4,500,000
Debt instrument, fee amount	4,000,000	4,000,000			$ 4,000,000
Line of credit facility, minimum cash requirement		10,000,000
Potential increase in interest rate					2.00%
Debt issuance costs, gross								$ 8,200,000
Remaining borrowing capacity	71,100,000	71,100,000			$ 71,100,000
Secured Debt | US Treasury Rate | Loan Agreement
Debt Instrument [Line Items]
Margin for term loan					0.50%
Secured Debt | Repayment of Interests | Loan Agreement
Debt Instrument [Line Items]
Capacity available for specific purpose other than for trade purchases	25,000,000	25,000,000			$ 25,000,000
Secured Debt | Payments Related to Litigation | Loan Agreement
Debt Instrument [Line Items]
Capacity available for specific purpose other than for trade purchases	$ 50,000,000	$ 50,000,000			$ 50,000,000
Secured Debt | Scenario, Forecast | Loan Agreement
Debt Instrument [Line Items]
Additional borrowing capacity						$ 5,000,000
Line of credit facility, minimum cash requirement			$ 20,000,000	$ 5,000,000

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ / shares in Units, shares in Millions	Sep. 02, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Exercise price of warrants	$ 2.29
Warrant liability		$ 11,466,162	$ 6,727,409
Loss from increase in fair value of warrant liability		$ 4,738,753	894,785	$ 0
Warrants
Class of Stock [Line Items]
Warrants purchased, value	4
Exercise price of warrants	$ 1.50
Class of warrant or right, outstanding	2.7
Exercisable period for warrants (in years)	10 years
Subscription Right | Warrants
Class of Stock [Line Items]
Exercise price of warrants	$ 1.50
Warrants
Class of Stock [Line Items]
Fair value assumptions, expected term		8 years 8 months 1 day
Warrant liability	$ 5,800,000	$ 11,500,000
Risk free interest rate (as a percent)	1.60%	2.38%
Expected dividend rate (as a percent)	0.00%	0.00%
Fair value assumptions, expected volatility rate	80.00%	75.00%
Loss from increase in fair value of warrant liability		$ 4,700,000	$ 900,000

Stockholders' Deficiency - Narr

Stockholders' Deficiency - Narrative (Details) - USD ($)	Nov. 16, 2016	Oct. 13, 2016	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Sep. 02, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Capital units, authorized				620,000,000
Common stock, shares authorized				600,000,000			600,000,000
Preferred stock, shares authorized				20,000,000
Exercise price of warrants						$ 2.29
Common Stock
Class of Warrant or Right [Line Items]
Issuance of common stock associated with rights offering, shares	23,523,195				23,523,195
Equity Rights
Class of Warrant or Right [Line Items]
Equity offering	$ 35,300,000
Common Stock | Subscription Right
Class of Warrant or Right [Line Items]
Amount to be invested by each right to purchase securities (in dollars per share)	$ 0.65
Exercise price of warrants	$ 1.50
Class of warrant or right, exercise price of warrants or rights, volume of weighted average price during market hours, percentage	85.00%
Private Placement
Class of Warrant or Right [Line Items]
Backstop fee			$ 1,764,240	$ 1,764,240
Private Placement | Common Stock
Class of Warrant or Right [Line Items]
Stock issued during period, shares, new issues		708,530
MacAndrews & Forbes | Private Placement | Common Stock
Class of Warrant or Right [Line Items]
Stock issued during period, shares, new issues		565,000

Stock Compensation Plans - Narr

Stock Compensation Plans - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	May 23, 2017	Apr. 25, 2012	May 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized					8,500,000	4,500,000	2,000,000
Stock-based compensation expense	$ 1,100	$ 800	$ 1,600
Performance-based stock options			200,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock options	73	0	$ 0
Total intrinsic value of stock options exercised	$ 65	$ 0	$ 6
Performance-based stock options	100,000	200,000
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of stock options exercised	$ 900
Number of shares granted	0			1,400,000
Weighted average grant-date fair value, granted				$ 0.68
Award vesting period				3 years
Maximum number of shares to be issued	162,393	360,031
Stock Appreciation Rights (SARs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				7 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining requisite service period (in years)	1 year 7 months 68 days
Number of shares granted	289,648
Weighted average grant-date fair value, granted	$ 3.51	$ 2.24	$ 2
Unrecognized stock-based compensation cost	$ 1,100
Vesting of RSU's, value	$ 600	$ 1,400	$ 1,800
Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year

Stock Compensation Plans (Stock

Stock Compensation Plans (Stock Plans and Stock Options) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,100,000	$ 800,000	$ 1,600,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period	1,709,967
Number of shares granted	25,000
Number of shares exercised	(33,870)
Number of shares canceled and expired	(638,630)
Number of shares outstanding at end of period	1,062,467	1,709,967
Number of shares vested and expected to vest	1,062,467
Number of shares exercisable	962,467
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price outstanding at beginning of period	$ 4.76
Weighted average exercise price, granted	3.50
Weighted average exercise price, exercised	2.64
Weighted average exercise price, canceled and expired	3.75
Weighted average exercise price outstanding at end of period	5.42	$ 4.76
Weighted average exercise price, vested and expected to vest	5.42
Weighted average exercise price, exercisable	$ 5.72
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining life, outstanding	1 year 9 months 22 days
Weighted average remaining life, vested and expected to vest	1 year 9 months 22 days
Weighted average remaining life, exercisable	1 year 10 months 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Intrinsic value, outstanding	$ 1,240
Intrinsic value, vested and expected to vest	1,240
Intrinsic value, exercisable	$ 1,004

Stock Compensation Plans (Sto52

Stock Compensation Plans (Stock Appreciation Rights) (Details) - Stock Appreciation Rights (SARs) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period	1,183,024
Number of shares granted	0	1,400,000
Number of shares exercised	(916,874)
Number of shares canceled and expired	0
Number of shares outstanding at end of period	266,150
Number of shares vested and expected to vest	266,150
Number of shares exercisable	266,150,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price outstanding at beginning of period	$ 3.53
Weighted average exercise price granted	0
Weighted average exercise price exercised	3.53
Weighted average exercise price canceled and expired	0
Weighted average exercise price outstanding at end of period	3.53
Weighted average exercise price, vested and expected to vest	3.53
Weighted average exercise price, exercisable	$ 3.53
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average remaining life, outstanding	1 year 1 month 2 days
Weighted average remaining life, vested and expected to vest	1 year 1 month 2 days
Weighted average remaining life, exercisable	1 year 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]
Intrinsic value outstanding	$ 0
Intrinsic value, vested and expected to vest	$ 0
Intrinsic value, exercisable	$ 0

Stock Compensation Plans (Restr

Stock Compensation Plans (Restricted Stock Awards and Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period	1,455,689
Number of shares granted	289,648
Number of shares vested and released	(273,335)
Number of shares canceled and expired	0
Number of shares outstanding at end of period	1,472,002	1,455,689
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average grant-date fair value outstanding at beginning of period	$ 2.36
Weighted average grant-date fair value, granted	3.51	$ 2.24	$ 2
Weighted average grant-date fair value, vested	2.21
Weighted averaged grant-date fair value, canceled and expired	0
Weighted average grant-date fair value outstanding at end of period	$ 2.61	$ 2.36
Number of shares vested and expected to vest	394,118

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	Dec. 22, 2017	Dec. 21, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21.00%	35.00%	35.00%	35.00%	35.00%
Deferred tax assets, alternative minimum tax			$ 2,652,250	$ 2,029,190
Valuation allowance, increase amount			53,000,000
Federal net operating loss carryforwards			174,300,000
Unrecognized tax benefits			$ 0		$ 0

Income Taxes Provision (Benefit

Income Taxes Provision (Benefit) for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current federal tax expense (benefit)	$ 623,060	$ (5,093)	$ 439,934
Current state and local tax expense (benefit)	1,179	(1,446)	946
Current income tax expense (benefit)	624,239	(6,539)	440,880
Deferred federal income tax expense (benefit)	(2,724,371)	21,252	19,006
Deferred state and local income tax expense (Benefit)	6,342	(829)	2,097
Deferred income tax expense (benefit)	(2,718,029)	20,423	21,103
Benefit from (provision for) income taxes	$ (2,093,790)	$ 13,884	$ 461,983

Income Taxes Deferred Tax Asset

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred income tax assets:
Net operating losses	$ 38,087,782	$ 72,726,440
Deferred research and development costs	205,527	669,602
Amortization of intangible assets	282,213	665,531
Share-based compensation	1,001,662	1,687,243
Fixed assets	417,085	667,008
Deferred revenue	84,130,212	102,520,433
Alternative minimum tax credits	2,652,250	2,029,190
Other	1,024,082	1,337,941
Deferred income tax assets	127,800,813	182,303,388
Deferred income tax assets, net of valuation allowance	(102,556,657)	(155,465,173)
Deferred income tax assets, net of valuation allowance	25,244,156	26,838,215
Deferred income tax liabilities:
Amortization of goodwill	(193,458)	(287,729)
Capitalized contract costs	(21,518,646)	(25,854,435)
Other	(1,100,089)	(982,117)
Deferred income tax asset (liability), net	$ 2,431,963
Deferred income tax asset (liability), net		$ 286,066

Income Taxes Effective Tax Rate

Income Taxes Effective Tax Rate Reconciliation (Details)	Dec. 22, 2017	Dec. 21, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate	(21.00%)	(35.00%)	(35.00%)	(35.00%)	(35.00%)
State tax benefit			(3.90%)	0.60%	(0.00%)
Increase in fair value of common stock warrants			4.30%	0.80%	(0.00%)
Reorganization costs			(0.00%)	3.30%	7.00%
Other			(1.80%)	0.20%	1.40%
U.S. federal tax law change			(5.10%)	(0.00%)	(0.00%)
Valuation allowance on deferred tax assets			36.00%	30.10%	27.80%
Effective tax rate			(5.50%)	(0.00%)	1.20%

Commitments and Contingencies (

Commitments and Contingencies (Details)	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	May 26, 2017ft²	Nov. 16, 2016USD ($)	Dec. 23, 2015USD ($)	Jan. 15, 2015USD ($)	Jan. 09, 2013ft²
Loss Contingencies [Line Items]
Rent expense	$ 1,000,000	$ 1,200,000	$ 1,400,000
License Agreement litigation | Settled Litigation
Loss Contingencies [Line Items]
Final order and judgment							$ 195,000,000
Final order and judgment post-judgment interest						$ 30,663.89
Final order and judgment including interest					$ 217,000,000
MacAndrews & Forbes
Loss Contingencies [Line Items]
Area of real estate property (in sq ft) | ft²								6,676
New HQ Lease | MacAndrews & Forbes
Loss Contingencies [Line Items]
Area of real estate property (in sq ft) | ft²				3,200

Commitments and Contingencies59

Commitments and Contingencies Operating Leases (Details)	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 571,705
2,019	596,237
2,020	347,259
2,021	349,422
2,022	368,467
Thereafter	1,788,749
Total	$ 4,021,839

Related Party Transactions (Det

Related Party Transactions (Details)	Jul. 31, 2017USD ($)	May 26, 2017USD ($)ft²	Oct. 13, 2016shares	May 31, 2017USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Nov. 16, 2016$ / shares	Jan. 09, 2013ft²
Member of Board of Directors
Related Party Transaction [Line Items]
Legal fees					$ 400,000			$ 1,500,000	$ 602,000
Accounts payable to related party					$ 35,000		$ 35,000
MacAndrews & Forbes
Related Party Transaction [Line Items]
Area of real estate property (in sq ft) | ft²											6,676
Rent expense, sublease rentals, net	$ 2,000,000
Rent expense, sublease rentals, estimate	2,400,000
Private Placement
Related Party Transaction [Line Items]
Payments of stock issuance costs						$ 1,764,240	1,764,240
Share price | $ / shares										$ 2.49
Common Stock | Private Placement
Related Party Transaction [Line Items]
Stock issued during period, shares, new issues | shares			708,530
Common Stock | Private Placement | MacAndrews & Forbes
Related Party Transaction [Line Items]
Stock issued during period, shares, new issues | shares			565,000
New HQ Lease | MacAndrews & Forbes
Related Party Transaction [Line Items]
Area of real estate property (in sq ft) | ft²		3,200
Monthly rental payments for initial period		$ 25,333
Monthly rental payments after initial period		29,333
Additional facility fee		$ 3,333
Facility fee annual increase, percent				5.00%
Facility fee after initial period				$ 0
Replacement M&F Sublease | MacAndrews & Forbes
Related Party Transaction [Line Items]
Monthly rental payments for initial period	36,996
Monthly rental payments after initial period	$ 37,831
Free rent period	2 months
Initial rent period	12 months
Monthly rental payments after secondary period	$ 38,665
Rent expense, sublease rentals	900,000
Old HQ Sublease
Related Party Transaction [Line Items]
Business exit costs						$ 1,100,000
Lease termination liability							$ 100,000
Old HQ Sublease | MacAndrews & Forbes
Related Party Transaction [Line Items]
Monthly rental payments for initial period	60,000
Monthly rental payments after initial period	63,400
Rent discrepancy, sublease rentals	$ 1,100,000

Related Party Transactions - Re

Related Party Transactions - Related Party Activity (Details) - MacAndrews & Forbes $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Related Party Transaction [Line Items]
Balance at December 31, 2016	$ 0
Charges	1,096,648
Cash payments	(282,026)
Balance at December 31, 2017	$ 814,622

Reorganization (Details)

Reorganization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reorganizations [Abstract]
Legal fees		$ 1,951,381	$ 5,719,052
Professional fees		1,732,521	2,027,827
Trustee fees		33,000	59,000
Other		0	5,672
Total	$ 0	3,716,902	7,811,551
Reorganization payments		$ 4,600,000	$ 6,700,000

Financial Information By Quar63

Financial Information By Quarter (Unaudited) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information [Abstract]
Research and development	$ 1,412,000	$ 1,390,000	$ 4,265,000	$ 5,202,000	$ 7,159,000	$ 4,658,000	$ 1,901,000	$ 1,270,000	$ 12,268,960	$ 14,987,628	$ 8,175,878
Selling, general and administrative expense	3,281,000	3,094,000	3,058,000	2,870,000	4,464,000	2,855,000	3,739,000	2,656,000	12,303,050	13,713,635	10,582,068
Research and development expense	2,781,000	2,471,000	5,068,000	6,360,000	8,158,000	6,069,000	2,948,000	2,536,000	16,679,712	19,710,673	13,130,529
Patent expenses	221,000	251,000	197,000	241,000	219,000	230,000	240,000	220,000	909,946	909,376	1,009,053
Lease termination	0	1,225,000	0	0					1,225,421	0	0
Interest on PharmAthene liability					927,000	3,566,000	4,259,000	2,917,000	0	11,668,900	0
Operating loss	(4,871,000)	(5,651,000)	(4,059,000)	(4,269,000)	(6,609,000)	(8,062,000)	(9,285,000)	(7,059,000)	(18,849,169)	(31,014,956)	(30,953,266)
Net income (loss)	$ (10,303,000)	$ (9,816,000)	$ (7,501,000)	$ (8,615,000)	$ (10,439,000)	$ (9,244,000)	$ (9,566,000)	$ (10,449,000)	$ (36,235,484)	$ (39,697,960)	$ (39,451,324)
Earnings (loss) per share: basic and diluted (usd per share)	$ (0.13)	$ (0.12)	$ (0.10)	$ (0.11)	$ (0.15)	$ (0.17)	$ (0.18)	$ (0.19)	$ (0.46)	$ (0.69)	$ (0.73)